DeepCure scores $40M for AI-enabled drug discovery


poba/Getty Images

poba/Getty Images

By Emily Olsen

DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.

The round was led by Morningside Ventures with participation from existing investors TLV Partners, Sapir Venture Partners and Benon Group Ltd.

DeepCure said the Series A brings its total raise to $47 million.

Related Content